THE Pharmaceutical Benefits Advisory Committee (PBAC) has voiced support for the listing of COVID-19 treatment, Lagevrio (molnupiravir) as a general schedule authority required (streamlined) benefit.
PBAC recommended that the drug be initially listed on the Pharmaceutical Benefits Scheme (PBS) for patients with mild to moderate COVID, not requiring supplemental oxygen, where treatment is commenced within five days of onset of symptoms, in Indigenous people age 50 years and older with two additional risk factors for developing severe disease, patents aged 65 years or older with two additional high-risk factors, people aged 75 years with a high-risk factor of developing severe disease, and moderately to severely immunocompromised patients.
PBAC noted that being unvaccinated or partially vaccinated was currently considered the greatest risk factor for developing severe infection.
CLICK HERE for more information.
The above article was sent to subscribers in Pharmacy Daily's issue from 28 Feb 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 28 Feb 22
